AspyreRx is the only FDA-authorized, fully digital, and therefore easily accessible and scalable, lifestyle intervention designed to improve type 2 diabetes (T2D) outcomes. It is backed by robust data from a randomized controlled trial (RCT) demonstrating clinically meaningful and sustained reduction in A1c as well as improvements in other markers of cardiometabolic health when used up to 180 days.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.